81 4 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO Conclusions DEX-sparing strategies with palonestron or multiple-day metoclopramide are safe and noninferior to DEX beyond 24h in terms of delayed TC rate in patients undergoing (oxaliplatin-based ) MEC. Therefore, these regimens are an alternative to standard treatment with multiple-day DEX. In conclusion, our study shows that a DEX-sparing strategy incorporating palonestron or multipleday metoclopramide is safe and noninferior to DEX beyond 24h in terms of delayed TC rate in patients undergoing MEC, mainly consisting of oxaliplatinbased chemotherapy. Therefore, these regimens might be an alternative to standard treatment with multiple-day DEX.
RkJQdWJsaXNoZXIy MjY0ODMw